image description

Press Releases

Press Releases

August 28, 2019
Revance to Participate in the Wells Fargo 14th Annual Healthcare Conference
NEWARK, Calif. --(BUSINESS WIRE)--Aug. 28, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the Wells Fargo 14th Annual Healthcare
July 17, 2019
Revance Adds Life Sciences Audit Executive Chris Nolet to Board of Directors
- Nolet will serve as Chair of the Audit Committee - NEWARK, Calif. --(BUSINESS WIRE)--Jul. 17, 2019-- ​ Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing a new category of high-performance neuromodulators for use in treating aesthetic and therapeutic conditions, today
June 6, 2019
Revance Adds Iconic Brand Builder Jill Beraud to Board of Directors
- Beraud will also chair newly-formed Brand Strategy Committee - NEWARK, Calif. --(BUSINESS WIRE)--Jun. 6, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing a new category of high-performance neuromodulators for use in treating aesthetic and therapeutic
May 14, 2019
Revance to Participate in the RBC Capital Markets 2019 Healthcare Conference
NEWARK, Calif. --(BUSINESS WIRE)--May 14, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the company will participate in the RBC Capital Markets 2019
Displaying 1 - 10 of 173